European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

AstraZeneca (AZN) and Amgen's (AMGN) Tezspire received a positive recommendation for EU approval for chronic rhinosinusitis with nasal polyps, based on Phase 3 data showing significant reductions in nasal polyp severity, surgery, and systemic corticosteroid use. Concurrently, AstraZeneca's Koselugo also secured an EU recommendation for adult neurofibromatosis type 1 patients with inoperable plexiform neurofibromas, demonstrating a 20% objective response rate in its KOMET Phase 3 trial. AstraZeneca shares reacted positively, rising 1.78% on the news.

Analysis

AstraZeneca has demonstrated significant regulatory momentum in the European Union, securing two positive recommendations from the EMA's Committee for Medicinal Products for Human Use (CHMP). The first recommendation for Tezspire, co-developed with Amgen, is for a new indication in chronic rhinosinusitis with nasal polyps (CRSwNP). This opinion is supported by compelling WAYPOINT Phase 3 trial data, which showed a statistically significant reduction in Nasal Polyp Score by -2.08 and nasal congestion by -1.04 versus placebo, alongside a near-complete (98%) reduction in the need for surgery. This potential label expansion builds on Tezspire's existing approval for severe asthma and is concurrently under review in the U.S., China, and Japan, signaling a broadening commercial opportunity. The second CHMP recommendation is for AstraZeneca's wholly-owned drug, Koselugo, for adult patients with neurofibromatosis type 1 (NF1). The KOMET Phase 3 trial underpinning this decision showed a 20% objective response rate compared to 5% with placebo. The market has reacted favorably to AstraZeneca's pipeline success, with its stock (AZN) rising 1.78%, while Amgen's stock (AMGN) saw a slight decline, suggesting investors are attributing the bulk of the value from these developments to AstraZeneca.

Key Decisions for Investors

• The dual positive recommendations strengthen the outlook for AstraZeneca's respiratory and oncology franchises, and investors should assess the potential for upward revisions to revenue forecasts pending final EU approvals and outcomes of parallel reviews in the U.S. and China.
• For Amgen investors, the muted stock reaction suggests the Tezspire label expansion may be fully priced in or that the market assigns a greater share of the commercial benefit to AstraZeneca; focus should be on the specific terms of the partnership and its net impact on Amgen's earnings.
• Given the positive clinical data and regulatory momentum, long-biased investors in AstraZeneca could view this as a validation of the company's R&D strategy and pipeline value, while those monitoring Amgen should scrutinize its broader portfolio for differentiated growth drivers.